FDA LungRx coverage for business development, investment, and market access teams
The FDA has granted approval for LungRx, an inhaled therapy that offers a groundbreaking treatment for pulmonary hypertension, enhancing patient care and outcomes.
We use cookies to enhance your experience, analyze traffic, and for marketing. By continuing to use our site, you consent to our use of cookies. Privacy Policy
